PH gov’t assessing best booster shot for Sinopharm vaccinees

Spread the love

MANILA – Malacañang said on Wednesday that the Philippine government is still waiting for data to prescribe the appropriate booster shots for people who received Sinopharm coronavirus vaccine as first doses.

Cabinet Secretary Karlo Nograles, acting presidential spokesperson, highlighted that vaccine manufacturers have not yet provided adequate information on which brands can be used as booster shots for those who had the Chinese-made vaccine as their initial dose series.

Even the Department of Health stated that no data on the subject is accessible elsewhere “abroad and in the country, even from Sinopharm”.

Nograles said that despite this, discussions between the National Vaccination Operations Center (NVOC) and manufacturers are ongoing.

“Tuloy-tuloy ang pakikipag-ugnayan at pakikipag-usap at paghingi natin ng additional data and information from the manufacturers ng Sinopharm para sa lalong madaling panahon ay makakapagbigay na ng abiso ang ating NVOC kung ano ung pinaka-mainam na booster shots para sa mga nakapag-kumpleto na ng two doses ng Sinopharm (Our discussion with the manufacturers are continuous so that we can provide recommendation as to the appropriate booster shots for those who got it as first two doses),” he said in an interview.

President Rodrigo Duterte was given Sinopharm as a booster dose, the same vaccine that he received for his primary series.

He had no adverse effects, but Nograles reiterated that the decision was made on the advice of Duterte’s physician.

“Wala naman pong masamang epektong naidulot sapagkat alam namin, again, itong mga bakuna ni Pangulong Duterte ay something between him and his personal physician (As far as we know no adverse effect has been reported, again, the vaccines of President Duterte are something that is between him and his personal physician),” he said.

House committees to hold hearings during break

Spread the love

Spread the loveMANILA – The House of Representatives has authorized for its committees to conduct hearings during the five-week congressional break, extending until late April.